Prandin (repaglinide), a new oral hypoglycemic for type 2 diabetes
You'll soon see Prandin (repaglinide), a new oral hypoglycemicfor type 2 diabetes...co-marketed by Novo Nordisk and Schering.
It's approved for monotherapy...and for use with metformin(Glucophage). It's also being tested with troglitazone (Rezulin).
Prandin is the first drug in a new class...the meglitinides.